ImmunoPET imaging of renal cell carcinoma with 124I- and 89Zr-Labeled Anti-CAIX monoclonal antibody cG250 in mice

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 7, 2013, Pages 510-515

  Stillebroer, Alexander B ^a   Franssen, Gerben M ^a   Mulders, Peter F A ^a   Oyen, Wim J G ^a   Van Dongen, Guus A M S ^b   Laverman, Peter ^a   Oosterwijk, Egbert ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

124I; 89Zr; cG250; immunoPET

Indexed keywords

CARBONATE DEHYDRATASE IX; GIRENTUXIMAB; GIRENTUXIMAB I 124; GIRENTUXIMAB ZR 89; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CAMERA; CANCER DIAGNOSIS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; GENE OVEREXPRESSION; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; ZIRCONIUM;

EID: 84881465677     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2013.1487     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225
2. Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470
3. Griffin N, Gore ME, Sohaib SA. Imaging in metastatic renal cell carcinoma. AJR Am J Roentgenol 2007;189:360
4. Powles T, Murray I, Brock C, et al. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007;51:1511
5. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinomaassociated antigen G250. Int J Cancer 2000;85:865
6. Brouwers AH, van Eerd JE, Frielink C, et al. Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 2004;45:327
7. Brouwers AH, Buijs WC, Oosterwijk E, et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: An intrapatient comparison. Clin Cancer Res 2003;9:3953s
8. Brouwers AH, Mulders PF, De Mulder PH, et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 2005;23:6540
9. Steffens MG, Boerman OC, De Mulder PH, et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999;5:3268s
10. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529
11. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol 2007;8:304
12. Brouwers A, Verel I, Van EJ, et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm 2004;19:155
13. Lawrentschuk N, Lee FT, Jones G, et al. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT. Urol Oncol 2011; 29:411
14. Divgi CR, Uzzo RG, Gatsonis C, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: Results from the REDECT trial. J Clin Oncol 2013;31:187
15. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renalcell carcinoma and absent from normal kidney. Int J Cancer 198615;38:489
16. Thiry A, Dogne JM, Masereel B, et al. Targeting tumorassociated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006;27:566
17. Verel I, Visser GW, Boellaard R, et al89Zr immuno-PET: Comprehensive procedures for the production of 89Zrlabeled monoclonal antibodies. J Nucl Med 2003;44:1271
18. Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77
19. Ebert T, Bander NH, Finstad CL, et al. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 1990;50:5531
20. Beniers AJ, Peelen WP, Schaafsma HE, et al. Establishment and characterization of five new human renal tumor xenografts. Am J Pathol 1992;140:483
21. Kranenborg MH, Boerman OC, De Weijert MC, et al. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts. Cancer 1997;80:2390
22. Visser EP, Disselhorst JA, Brom M, et al. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med 2009;50:139
23. Sharkey RM, Behr TM, Mattes MJ, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997;44:179
24. Shih LB, Thorpe SR, Griffiths GL, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: A comparison of nine radiolabels. J Nucl Med 1994;35:899
25. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56:2123
26. Perk LR, Vosjan MJ, Visser GW, et al. p- Isothiocyanatobenzyldesferrioxamine: A new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging 2010; 37:250
27. Verel I, Visser GW, Boellaard R, et al. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 2003; 44:1663.